Skip to content
353 1 5677201
info@irishthoracicsociety.com
ITS Annual Meeting
Linkedin
Twitter
About Us
About Us
Council
Past Presidents
Honourary Awards
Membership
News & Events
Education
ITS – GSK – ERS Travel Bursaries 2024
Irish Thoracic Society Flashcards
Video Resources
Irish Thoracic Society Guidelines
Irish Thoracic Society Online Journal Club
Respiratory Health of the Nation 2018
Respiratory Health of the Nation by Chapter
Research & Innovation
Irish Thoracic Society Research Mission
ITS Call under HRCI HRB Joint Funding Scheme 2023-24
ITS Public Patient Involvement Overview
Joint Funding Scheme completed projects
Previous Research Grants
Advocacy
Patient Resources
Asthma
COPD
Lung Cancer
Pneumonia
Tuberculosis
Cystic-Fibrosis
Obstructive Sleep Apnoea
Interstitial Lung Diseases
Influenza
Alpha-1 Antitrypsin Deficiency
Links
Menu
About Us
About Us
Council
Past Presidents
Honourary Awards
Membership
News & Events
Education
ITS – GSK – ERS Travel Bursaries 2024
Irish Thoracic Society Flashcards
Video Resources
Irish Thoracic Society Guidelines
Irish Thoracic Society Online Journal Club
Respiratory Health of the Nation 2018
Respiratory Health of the Nation by Chapter
Research & Innovation
Irish Thoracic Society Research Mission
ITS Call under HRCI HRB Joint Funding Scheme 2023-24
ITS Public Patient Involvement Overview
Joint Funding Scheme completed projects
Previous Research Grants
Advocacy
Patient Resources
Asthma
COPD
Lung Cancer
Pneumonia
Tuberculosis
Cystic-Fibrosis
Obstructive Sleep Apnoea
Interstitial Lung Diseases
Influenza
Alpha-1 Antitrypsin Deficiency
Links
Indications for cessation and/or dose reduction for adverse events from Nintedanib for the treatment for Idiopathic Pulmonary Fibrosis
